News
Aerys Biosciences at JPM 2026 San Francisco.
Rabindra Shivnaraine, Director of Clinical Pharmacology at Aerys Biosciences, attended the 2026 J.P.
A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Participants with Idiopathic Pulmonary Fibrosis (SAFE-IPF)
Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease resulting in
Aerys Biosciences at OCT West Coast 2026
Rabindra Shivnaraine, PhD, Director of Clinical Pharmacology at Aerys Biosciences, spoke at Outsourcing
Aerys Biosciences at the Pulmonary Fibrosis Foundation Summit – 25th Anniversary
Robin Shivnaraine, PhD, Director of Clinical Pharmacology at Aerys Biosciences, attended the 25th
Have Any Questions?
Reach out to learn more about our work and ongoing initiatives.